Mark Sheptoff Financial Planning LLC Decreases Holdings in Pfizer Inc. (NYSE:PFE)

Mark Sheptoff Financial Planning LLC decreased its position in Pfizer Inc. (NYSE:PFE) by 16.1% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 20,788 shares of the biopharmaceutical company’s stock after selling 3,990 shares during the quarter. Mark Sheptoff Financial Planning LLC’s holdings in Pfizer were worth $598,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Corient Private Wealth LLC lifted its stake in shares of Pfizer by 0.8% in the 3rd quarter. Corient Private Wealth LLC now owns 3,163,739 shares of the biopharmaceutical company’s stock valued at $104,927,000 after acquiring an additional 25,534 shares during the last quarter. Syon Capital LLC bought a new stake in Pfizer in the third quarter valued at approximately $1,011,000. NBC Securities Inc. purchased a new stake in shares of Pfizer during the third quarter valued at approximately $2,361,000. Pinnacle Financial Partners Inc grew its holdings in shares of Pfizer by 3.9% in the third quarter. Pinnacle Financial Partners Inc now owns 438,863 shares of the biopharmaceutical company’s stock worth $14,557,000 after purchasing an additional 16,558 shares during the last quarter. Finally, Briaud Financial Planning Inc purchased a new position in shares of Pfizer in the third quarter worth $30,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE PFE traded down $0.80 during trading hours on Thursday, hitting $28.80. The company’s stock had a trading volume of 28,362,961 shares, compared to its average volume of 42,412,793. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $40.37. The company’s 50 day simple moving average is $27.24 and its two-hundred day simple moving average is $27.97. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The company has a market cap of $163.20 billion, a P/E ratio of -480.75, a price-to-earnings-growth ratio of 1.11 and a beta of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The firm had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.23 earnings per share. As a group, sell-side analysts expect that Pfizer Inc. will post 2.39 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be issued a dividend of $0.42 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.68 annualized dividend and a dividend yield of 5.83%. Pfizer’s payout ratio is -2,799.53%.

Analysts Set New Price Targets

PFE has been the subject of a number of analyst reports. Morgan Stanley increased their target price on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 price objective (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Guggenheim assumed coverage on Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Ten research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus target price of $35.86.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.